Minnesota Oncology and Virginia Piper Cancer Institute in Minneapolis are seeking participants for a study aiming to try to better understand, prevent and improve "chemo brain." (What is chemo brain?)
They will begin enrolling subjects on Monday, February 22 in the new study, called Focus Forward Cognitive PreHab.
To be considered for the study, patients must meet the following criteria:
- Have been diagnosed with breast cancer or ovarian cancer, which represents a first cancer diagnosis and not a recurrence
- Are scheduled to receive 1 of the following chemotherapy regimens for breast or ovarian cancer:
- Taxotere and cyclophosphamide (Cytoxan) (TC)
- Doxorubicin hydrochloride (Adriamycin) and cyclophosphamide (AC)
- Adriamycin and cyclophosphamide (Cytoxan) followed by Taxol (AC-T)
- Taxotere, Carboplatin, Herceptin (TCH)
- Paclitaxel and Carboplatin (6 cycles)
- Be at least 18 years of age
- Speak English
- Be able to see and hear (with or without correction/hearing device)
Exclusion criteria:
- Untreated/unstable psychiatric disorder
- Known cognitive deficits from other conditions, including metastases to brain
To find out more about this study or apply to be a participant, contact Karen Swenson, PhD, RN (612-863-5658) or Mary Radomski, PhD, OTR/L (612-863-3291).
Share
Categories
Tags
Recent Posts
A lung cancer guide to help in gathering the information you need to make informed choices for your treatment journey.
Lung cancer is the leading cause of all cancer deaths in the United States. Research has found that high risk people who get low-dose CT scans of the chest had a 20% lower chance of dying from lung cancer than those who got only chest X-rays.
In collaboration with computer scientists from the University of Central Florida, Mayo Clinic radiology and gastroenterology experts have developed an algorithm that can identify pancreatic cysts that are at higher risk of developing into pancreatic cancer.